"No Increase In Stroke With Anti-VEGF Tx For Eye Disorders" - Molly Walker
Recent research has found that the incidence of stroke did not increase among patients receiving anti-VEGF therapy compared with matched controls. A retrospective chart review found a smaller portion of patients receiving intravitreal injections with anti-VEGF agents suffered a stroke compared with a group of matched controls who did not receive the same therapies. Richard Rosen, MD, professor of ophthalmology at the Icahn School of Medicine at Mount Sinai and director of ophthalmology research at the New York Eye and Ear Infirmary of Mount Sinai, characterized these findings as “a nice demonstration of what we’ve known clinically.” Dr. Rosen, who was not involved in the study, added that the concern with anti-VEGF treatments, which were first used in cancer patients, was that they had the potential to interfere with coagulation. “These findings are reassuring for both the physician and the patient – that this treatment is not putting them at increased risk.”
- Richard B. Rosen, MD, Professor, Ophthalmology, Icahn School of Medicine at Mount Sinai, Surgeon-Director, Retina Service Chief, Director of Ophthalmology Research, New York Eye and Ear Infirmary of Mount Sinai
Blinding Eye Disease Strongly Associated With Serious Forms of Cardiovascular Disease
Nov 17, 2022 View All Press Releases
High-Tech Imaging Offers New Way to Detect Signs of Early Glaucoma
Aug 02, 2022 View All Press Releases
Blinding Eye Disease Is Strongly Associated With Heart Disease and Stroke
Jul 12, 2022 View All Press Releases
Mount Sinai Recruits Internationally Recognized Ophthalmologists to Expand Leadership
Dec 17, 2018 View All Press Releases